SLE is a chronic autoimmune illness that affects several systems. Gastrointestinal abnormalities, although uncommon, can be dangerous and frequently go undiagnosed due to vague symptoms. Lupus enteritis and peritonitis are serious consequences. Lupus enteritis affects up to 9.7% of SLE patients and causes stomach discomfort, nausea, and diarrhea. It frequently involves intestinal vasculitis, which results in gut wall thickening and, in extreme instances, ischemia or perforation. Lupus peritonitis is very uncommon. Differentiating them from other causes of stomach discomfort is critical. This case emphasizes the diagnostic problems, imaging results, and the significance of early, focused therapy for better outcomes.

To assess the incidence and risk of nephrolithiasis in people receiving uricosuric therapies for gout.

The optimal starting dose and tapering of glucocorticoids (GC) in lupus nephritis (LN) remains unknown. We aimed to assess whether a higher prednisone dose results in better 12-month complete renal response (CRR) rates compared with a lower dose, in a contemporary multicentre cohort of LN patients.

This systematic review and meta-analysis examined how axial spondyloarthritis (axSpA), and its specific disease features, impact sexual function.

To evaluate MyRA, a web-based self-monitoring application for rheumatoid arthritis, on patient empowerment, usability, and perceived usefulness.

This study aimed to clarify the activation profile of inflammasome-associated genes in systemic juvenile idiopathic arthritis (s-JIA).

Still's disease (SD) is an autoinflammatory disease (AID) that can lead to life-threatening macrophage activation syndrome (MAS). The role of procalcitonin (PCT) in AIDs remains unclear. This study aims to explore the relationship between non-infectious PCT elevation and clinical features of SD.

This study aimed to assess the risk of hospitalisation with pneumonia (HP) among patients with giant cell arteritis (GCA) and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV).

Interstitial lung disease (ILD) is a frequent complication in both anti-synthetase syndrome (ASyS) and primary Sjögren's disease (pSjD), but the clinical and molecular phenotype of patients with overlapping ASyS and pSjD (ASyS-SjD) remains poorly defined. This study aimed to characterize the clinical, serological, radiological, and transcriptomic features of ASyS-SjD patients with ILD, and to determine whether this overlap represents a distinct disease entity.

We evaluated the efficacy of Janus kinase inhibitors (JAKi) compared with tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA) patients with poor-prognosis factors (PPFs), including ACPA or RF positivity, Clinical Disease Activity Index (CDAI) ≥22, CRP ≥0.6 mg/dl, and HAQ-DI ≥0.5. We focused on treatment continuation, disease control, and glucocorticoid (GC) reduction.

Anti-neutrophil cytoplasmic antibody- (ANCA-) associated vasculitis (AAV) is a group of chronic multisystem inflammatory disorders affecting multiple organs throughout the body. Despite advances in AAV therapies, patients with AAV continue to experience higher rates of mortality than the general population. AAV outcomes can be improved by providing patients with rapid access to multidisciplinary medical teams and early treatment with glucocorticoid- (GC-) based therapy. However, GC are associated with a high risk of toxicity. The phase 3 ADVOCATE trial demonstrates that blocking the alternative complement pathways using avacopan alongside immunosuppression enables patients with AAV to reduce their GC exposure without compromising efficacy or safety outcomes. ADVOCATE subgroup analyses show benefits for avacopan in patients with a wide range of AAV-related manifestations, disease stages and ages, with the greatest benefits in patients with kidney impairment, lung manifestations, and AAV relapse.

To assess the progression of the interstitial lung disease related to rheumatoid arthritis (RA-ILD) with Methotrexate (MTX) exposure, and to evaluate the lung involvement in RA non-ILD patients with MTX exposure.

Cardiopulmonary involvement is the leading cause of mortality in systemic sclerosis (SSc), and early detection of interstitial lung disease (ILD) is critical to improving outcomes. Conventional spirometry has limitations, whereas impulse oscillometry (IOS) could provide a non-invasive, effort-independent method to detect and monitor pulmonary involvement in these patients. We aimed to evaluate IOS parameters in SSc-ILD, comparing their performance with conventional spirometry.